Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease.
Current opinion in nephrology and hypertension（2023）
Abstract
An influx of incretin-based therapies has changed the landscape of DKD treatment. GLP-1 receptor agonist use is endorsed by all major guideline forming organizations. Ongoing clinical trials and mechanistic studies with GLP-1 and dual GLP-1/GIP receptor agonists will further define the roles and pathways for these agents in the treatment of DKD.
MoreTranslated text
Key words
incretin therapies,chronic kidney disease,diabetes,kidney disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined